Search

Scientists at the Sloan Kettering Institute have discovered that the ability of cancers to metastasize to other organs is dependent upon their ability to co-opt natural wound-healing pathways. In a literal sense, metastasis is wound healing gone wrong. These findings provide a novel framework for thinking about metastasis and how to treat it.

… Monday, January 13, 2020 Bottom Line:  Scientists at the Sloan Kettering Institute have discovered that the ability of cancers to metastasize to other organs is dependent upon their ability to co-opt natural wound-healing pathways. In a literal sense, metastasis is wound healing gone wrong. These findings

Jae Park, MD, a hematologic oncologist and assistant attending physician at MSK, will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American Association for Cancer Research (AACR) Annual Meeting. This research has been selected to be featured in the meeting’s press program.

… Monday, April 3, 2017 Jae Park, MD , a hematologic oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center (MSK), will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American

Paige Arnold, a graduate student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), is one of 13 PhD candidates selected from around the world to receive a Harold M. Weintraub Graduate Student Award for the quality, originality, and significance of their doctoral research.

… Wednesday, March 2, 2022 Paige Arnold , a graduate student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), is one of 13 PhD candidates selected from around the world to receive a Harold M. Weintraub Graduate Student Award for the quality, originality, and significance of

A new drug could be an effective treatment for some people with low-grade glioma.

… Wednesday, August 7, 2024 Brain tumors are among the deadliest and most difficult cancers to treat. But the US Food and Drug Administration (FDA) has now approved a new drug that slows the growth of low-grade diffuse gliomas with a certain gene mutation.  “This represents the first new treatment option

By deciphering the biology of T cells, MSK scientists gave immunotherapy a boost.

… Wednesday, December 28, 2016 Immunologists are fond of car analogies. The T cells that protect us from infections and cancer, they say, have an ignition switch. They also have gas pedals and brakes. How immunologists, like good molecular mechanics, deciphered what makes T cells hum is a story that reaches

Cell replacement therapy seeks to restore function in the body by replacing cells that are lost due to disease or injury with new, healthy cells. One disease for which this type of therapy holds particular promise is the degenerative neurological disorder Parkinson’s disease, which is characterized by symptoms related to movement.

… Tuesday, August 21, 2012 Summary Cell replacement therapy seeks to restore function in the body by replacing cells that are lost due to disease or injury with new, healthy cells. One disease for which this type of therapy holds particular promise is the degenerative neurological disorder Parkinson’s

Studies conducted in mice reveal a potential way to breach the defenses of pancreatic cancer tumors.

… Tuesday, March 31, 2020 Summary In a study published March 31, researchers at the Sloan Kettering Institute report that a two-drug combination makes pancreatic cancer more sensitive to immunotherapy in mouse models. Pancreatic cancer is one of the most challenging cancers to treat. In part, that’s because

Learn how highly focused, intense radiation can stop lung cancer from growing after it has spread to a small number of sites.

… Thursday, December 14, 2023 Non-small cell lung cancer (NSCLC) , the most common form of lung cancer , is often diagnosed at an advanced  stage . About half the time, it has already spread around the body and has reached stage 4. The standard treatment for most patients with metastatic NSCLC is systemic

Obtenga información sobre cómo la radiación intensamente focalizada y de alta dosis puede detener el crecimiento del cáncer pulmonar después de que se ha diseminado a una pequeña cantidad de sitios.

… Thursday, December 14, 2023 El cáncer pulmonar de células no pequeñas (CPCNP) , la forma más común de cáncer pulmonar , suele diagnosticarse en un estadio  avanzado . Aproximadamente la mitad de las veces, ya se ha diseminado por el cuerpo y ha alcanzado el estadio 4. El tratamiento convencional para

Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan Kettering's history.

… Wednesday, May 10, 2006 Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering’s new cancer research facility, including